CDKN2A and neoplasm: In ATC, p16-negative status increased the risk of disease-specific mortality (HR, 35.25; 95% CI, 1.38–898.79) after adjusting the age at surgery and sex, although the statistical significance was lost without adjustment for covariates or after additional adjustments for distant metastasis and tumor origin (Supplementary Table 3).